Schrödinger (SDGR) Stock Analysis & Winston Score

Schrödinger makes software that uses physics and computer simulations to help scientists discover new drugs and materials. Instead of running thousands of expensive lab experiments, researchers use Schrödinger's platform to virtually test how molecules behave before ever touching a test tube. Its main customers are large pharmaceutical companies, biotech firms, and materials science companies looking to speed up their research. The company earns money two ways: software licenses and subscriptions sold to outside customers, plus a share of drug development milestones and royalties from its own internal drug pipeline built using the same tools. Schrödinger operates globally but is headquartered in New York, with a market cap around $1.1 billion. Its deep physics-based simulation technology is difficult to replicate, giving it a defensible position against simpler competitors. The key risk is that the company is burning cash heavily — with an operating margin of nearly -65% — and its path to profitability depends on both growing software sales and successfully advancing its drug candidates through clinical trials.